Journal
EUROSURVEILLANCE
Volume 23, Issue 5, Pages 2-8Publisher
EUR CENTRE DIS PREVENTION & CONTROL
DOI: 10.2807/1560-7917.ES.2018.23.5.18-00035
Keywords
-
Categories
Funding
- British Columbia Centre for Disease Control
- Alberta Health and Wellness
- Public Health Ontario
- Ministere de la sante et des services sociaux du Quebec
- l'Institut national de sante publique du Quebec
Ask authors/readers for more resources
Using a test-negative design, we assessed interim vaccine effectiveness (VE) for the 2017/18 epidemic of co-circulating influenza A(H3N2) and B(Yamagata) viruses. Adjusted VE for influenza A(H3N2), driven by a predominant subgroup of clade 3C.2a viruses with T131K + R142K + R261Q substitutions, was low at 17% (95% confidence interval (CI): -14 to 40). Adjusted VE for influenza B was higher at 55% (95% CI: 38 to 68) despite prominent use of trivalent vaccine containing lineage-mismatched influenza B(Victoria) antigen, suggesting cross-lineage protection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
